U.S. Physical Therapy (USPH) Q1 2026 earnings review
Topline Decelerates While Complex Equity Structure Crushes EPS
U.S. Physical Therapy posted stable volume growth in Q1 2026, with total revenue up 7.9% to $198.3M, driven by solid patient visit metrics and Industrial Injury Prevention (IIP) segment expansion. However, the bottom line tells a messy story. A GAAP net loss of $0.12 per share shocked against last year's $0.80 profit. This reversal wasn't purely operational—Adjusted EBITDA actually grew 3.6% to $20.2M—but stemmed from a $9.4M revaluation charge on redeemable non-controlling interests (partners' stakes) and negative earn-out swings. While management reaffirmed FY26 EBITDA guidance of $102-$106M, the widening gap between steady clinic performance and highly volatile GAAP earnings remains a heavy anchor for investors.
🐂 Bull Case
Clinic volumes remain structurally sound. Total patient visits grew 6.9% YoY to 1.54 million, and average daily visits per clinic edged up to 31.8 from 31.2. The underlying demand for services continues to expand.
The company's two previously announced hospital affiliations will begin their phased ramp-up in May 2026. Once fully integrated, these are expected to contribute at least $7.3M in annualized EBITDA to USPH's bottom line.
🐻 Bear Case
Massive swings in contingent earn-outs and non-controlling interest valuations routinely obscure underlying cash generation and crush GAAP EPS. This structural complexity deters investors seeking clean earnings visibility.
Adjusted physical therapy gross margins decelerated to 16.1% (from 16.8% a year ago). Rising operating costs per visit are currently outpacing the slight improvements in reimbursement rates.
⚖️ Verdict: ⚪
Neutral. The underlying PT and IIP businesses are stable and generating cash, but decelerating top-line momentum, reversing core margins, and wildly unpredictable GAAP accounting adjustments make the stock difficult to underwrite cleanly.
Key Themes
Physical Therapy Margin Compression
Despite a 6.9% increase in patient visits and higher daily clinic volumes, Physical Therapy margins are reversing. Adjusted PT gross margin compressed from 16.8% in 25Q1 to 16.1% in 26Q1. The data clearly contradicts any narrative of scale leverage: adjusted operating costs per visit rose 1.7% to $90.31, outpacing a meager 0.8% gain in net rate per visit ($106.49).
Industrial Injury Prevention (IIP) Expansion
The IIP segment continues to act as a robust counterweight to clinic pressures. Revenue is accelerating, growing 11.8% YoY to $30.6M, driven by strong 8.2% same-store growth. Crucially, IIP gross margin expanded sharply from 18.6% to 20.4%. This high-margin, capital-light business is effectively cross-subsidizing the margin compression felt in the core PT clinics.
Weak Macro Pricing Power
The company is facing macro-level headwinds in reimbursement. The net rate per physical therapy visit barely edged up 0.8% YoY. In previous quarters, management cited a 1.75% expected Medicare rate increase for 2026, but the actual realized Q1 total rate suggests that commercial and workers' comp negotiations are struggling to offset broader medical inflation and rising salary costs.
Phantom Losses and Earnings Volatility
The revaluation of redeemable non-controlling interests (representing subsidiary partners' stakes) triggered a massive $9.4M charge to retained earnings, plunging the company into a GAAP loss. While this does not impact Adjusted EBITDA or cash flow, the persistent, wild volatility from these equity structures and contingent earn-outs introduces severe earnings unpredictability.
Ambient AI and Front-Desk Virtualization
To combat rising labor costs, management highlighted the company-wide rollout of ambient-listening AI technology for clinical documentation and a partial virtualization of the front desk. These specific technological innovations are critical drivers required to reverse current margin compression by improving therapist throughput and reducing administrative headcount.
Medicare Remote Therapeutic Monitoring (RTM)
The company is launching Remote Therapeutic Monitoring (RTM) for traditional Medicare patients. This operational initiative facilitates better home program adherence while generating an entirely new, high-margin revenue stream that does not require additional physical clinic capacity.
Other KPIs
Grew by 3.6% YoY. While technically positive, this represents a severe deceleration from the mid-teens double-digit EBITDA growth seen throughout 2025. Rising corporate office costs, which expanded to 9.2% of total revenue (up from 8.8%), partially weighed on the profitability gains generated by the IIP segment.
Cash declined sequentially from $35.6M at the end of FY25. However, liquidity is stable. On April 14, the company closed on a significantly upsized $450.0M credit facility (extending maturity to 2031). Outstanding borrowings sit at $203.9M, indicating a highly manageable leverage profile given the $100M+ annual EBITDA run-rate.
Guidance
Reaffirmed. The midpoint of $104.0M implies an accelerating ~9.5% YoY growth against FY25's $95.0M. Management is heavily relying on the second half of the year to achieve this acceleration, banking on the phased ramp-up of the Metro and subsidiary hospital alliances starting in May 2026, as well as cost savings from recent tech implementations.
Key Questions
Pricing Power Disconnect
Why did the net rate per PT visit only increase 0.8% YoY in Q1 despite the implementation of the anticipated January 2026 Medicare rate update?
GAAP Earnings Predictability
At what point does the revaluation of redeemable non-controlling interests stabilize, or should investors expect extreme GAAP EPS volatility as a permanent feature of the business model?
AI Margin Impact
Can you quantify the expected margin benefit in H2 2026 from the ambient-listening AI and front-desk virtualization initiatives, and how much of this will flow to the bottom line versus offsetting wage inflation?
PT Gross Margin Defense
With PT operating costs per visit currently accelerating faster than reimbursement rates, what specific structural levers are you pulling to prevent further gross margin compression in the core clinic business?